Why the study?
Do vasoactive drugs (glyceryl trinitrate, propranolol, tolazoline, phentolamine, and intensain) affect human platelet behaviour?
Do vasoactive drugs (glyceryl trinitrate, propranolol, tolazoline, phentolamine, and intensain) affect human platelet behaviour?
Several vasoactive drugs used in cardiovascular disease demonstrate inhibitory effects on human platelet aggregation and electrophoretic mobility.
Hypothesis-generating in animals; leaves open whether these vasoactive drugs modulate human platelet behaviour or thrombosis risk.
A group of vasoactive drugs, commonly used in vascular disease, have been shown to affect human platelet behaviour. Glyceryl trinitrate, propranolol, tolazoline, phentolamine, and intensain inhibit platelet aggregation in vitro, and both in vitro and in vivo prevent adenosine diphosphate and noradrenaline from altering platelet electrophoretic mobility. The theoretical and practical implications are discussed.
No takes yet. Share an insight, caveat, or question.
Hampton et al. (1967) studied this question.
Synapse has enriched one closely related paper. Consider it for comparative context: